Relay Therapeutics (RLAY) Other Accumulated Expenses (2021 - 2026)

Relay Therapeutics (RLAY) has reported Other Accumulated Expenses for 6 consecutive years, with $847000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Accumulated Expenses fell 49.64% year-over-year to $847000.0; the TTM figure through Mar 2026 stood at $847000.0 (down 49.64% YoY), while the FY2025 annual figure was $463000.0, down 76.73% from the prior year.
• Other Accumulated Expenses improved to $847000.0 in Q1 2026 per RLAY's latest filing, from $463000.0 in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $26.9 million in Q3 2022 and bottomed at $463000.0 in Q4 2025.
• Historically, Other Accumulated Expenses has averaged $8.8 million across 5 years, with a median of $1.7 million in 2024.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses soared 6504.04% — and 2024, when it slumped 96.96%.
• Relay Therapeutics' Other Accumulated Expenses stood at $26.2 million in 2022, then sank by 95.4% to $1.2 million in 2023, then soared by 65.28% to $2.0 million in 2024, then plunged by 76.73% to $463000.0 in 2025, then surged by 82.94% to $847000.0 in 2026.
• Business Quant data shows RLAY's Other Accumulated Expenses at $847000.0 in Q1 2026, $463000.0 in Q4 2025, and $1.1 million in Q3 2025.